CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A.
Alajati A, et al. Among authors: hirabayashi s.
J Clin Invest. 2020 May 1;130(5):2435-2450. doi: 10.1172/JCI131133.
J Clin Invest. 2020.
PMID: 32250342
Free PMC article.